Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST

Journal of Clinical Oncology

Volumn 22, Issue 22, 2004, Pages 4442-4445

  Ratain, Mark J ^a   Eckhardt, S Gail ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DIHYDROFOLATE REDUCTASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRAMUSTINE; ESTROGEN RECEPTOR; FLUOROURACIL; GEFITINIB; IMATINIB; MERCAPTOPURINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

BONE MARROW SUPPRESSION; CANCER RESEARCH; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; DIARRHEA; DNA ALKYLATION; DRUG DEVELOPMENT; DRUG TARGETING; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; RASH; BIOASSAY; CLINICAL TRIAL; DRUG INDUSTRY; METHODOLOGY; NEOPLASM; NOTE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG INDUSTRY; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 16544380415     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.960     Document Type: Editorial

References (19)

1. Jacobson LO, Spurr CL, Barron ESG, et al: Studies on the effect of methyl-bis(beta-chloroethyl)amine hydrochloride on neoplastic diseases and allied disorders of the hemopoietic system. JAMA 132:263-271, 1946
2. Gilman A, Phillips FS: The biological actions and therapeutic applications of the β-chloroethyl amines and sulfides. Science 103:409-415, 1946
3. Farber S, Diamond LK, Mercer RD, et al: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin). N Engl J Med 238:787-793, 1948
4. Elion GB, Hitchings GH: Antagonists of nucleic acid derivatives, IV: Reversal studies with 2-aminopurine and 2,6-diaminopurine. J Biol Chem 187:511-522, 1950
5. Heidelberger C, Griesbach L, Montag BJ, et al: Studies on fluorinated pyrimidines. II: Effects on transplanted tumors. Cancer Res 18:305-317, 1958
6. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
7. Tew KD. Erickson LC, White G, et al: Cytotoxicity of estramustine, a steroid-nitrogen mustard derivative, through non-DNA targets. Mol Pharmacol 24:324-328, 1983
8. Eisenhauer EA, O'Dwyer PJ, Christian M, et al: Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684-692, 2000
9. Temple R: Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trials. Am Heart J 139:5133-5135, 2000
10. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase. II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
11. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
12. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
14. Rosner GL, Stadler W, Ratain MJ: Randomized discontinuation design: Application to cytostatic antineoplastic agents. J Clin Oncol 20:4478-4484, 2002
15. Ratain MJ, Flaherty KT, Stadler WM, et al: Preliminary antitumor activity of BAY43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial. Proc Am Soc Clin Oncol 23:381, 2004 (abstr 4501)
16. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
17. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
18. Rinehart J, Adjei AA, LoRusso PM, et al: Multicenter phase II study of the oral mitogen-activated extracellular signal regulated kinase inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456-4462, 2004
19. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989